Trial Profile
A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Valopicitabine (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 19 Nov 2014 New trial record